Detalles de la búsqueda
1.
Short- and mid-term morbidity and primary-care burden due to infant respiratory syncytial virus infection: A Spanish 6-year population-based longitudinal study.
Pediatr Allergy Immunol
; 35(5): e14131, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38700124
2.
Effectiveness and impact of universal prophylaxis with nirsevimab in infants against hospitalisation for respiratory syncytial virus in Galicia, Spain: initial results of a population-based longitudinal study.
Lancet Infect Dis
; 2024 Apr 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-38701823
3.
Assessment of effectiveness and impact of universal prophylaxis with nirsevimab for prevention of hospitalizations due to respiratory syncytial virus in infants. The NIRSE-GAL study protocol.
Hum Vaccin Immunother
; 20(1): 2348135, 2024 Dec 31.
Artículo
en Inglés
| MEDLINE | ID: mdl-38738683
Resultados
1 -
3
de 3
1
Próxima >
>>